Exscientia

By Dave Muoio 12:21 pm May 26, 2020
insitro and Exscientia, two platforms using artificial intelligence to drive the discovery of new drugs, announced this morning the raise of $143 million and $60 million, respectively, from investors. insitro's oversubscribed Series B round was headed by Andreessen Horowitz, and joined by new backers Canada Pension Plan Investment Board, T. Rowe Price Associates, BlackRock, Casdin Capital, HOF...

Credit: Bayer AG

By Leontina Postelnicu 07:56 am January 10, 2020
German pharma giant Bayer and British biotech firm Exscientia have announced a three-year partnership focused on the use of Artificial Intelligence in cardiovascular and oncology drug discovery. The collaboration will initially see the companies work on three early-stage research projects, combining Bayer’s data and drug discovery capabilities and Exscientia’s Centaur Chemist platform. According...